secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001013762-24-003209
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal stockholders approve reverse split, share increase, and equity plan amendment
--------------------------------------------------------------------------------

- Approved reverse stock split at Board's discretion (1:2 to 1:20 ratio).
- Authorized share increase from 75M to 125M shares of common stock.
- Equity plan amendment adds 2,000,000 shares (total 4,604,550) and modifies evergreen provision to 20% of outstanding plus warrant shares.
- Elected directors John Murphy and Robert Lisicki to Class II until 2027.
- Ratified WithumSmith+Brown as independent auditor for 2024 fiscal year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000101376224003209/0001013762-24-003209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000101376224003209/ea0210326-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001013762-24-003209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer